02041nas a2200385   4500000000100000008004100001260001300042653002600055653002400081653002300105653001600128653003000144653001800174653001600192653001100208653002200219653001300241653002300254653001200277653002500289653002000314653000900334653002400343100001700367700002800384700002100412700002200433245009200455856012300547300001100670490000800681050005300689520089900742022001401641       2013                            d  c2013 Sep10aAntibodies, Bacterial10aAntigens, Bacterial10aBacterial Vaccines10aBCG Vaccine10aDrug Therapy, Combination10aGlobal health10aGlycolipids10aHumans10aIntradermal Tests10aLepromin10aLeprostatic Agents10aleprosy10aMycobacterium leprae10aSerologic Tests10aSkin10aSpecies Specificity1 aEichelmann K1 aGonzález González S E1 aSalas-Alanis J C1 aOcampo-Candiani J00aLeprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment.  uhttp://www.actasdermo.org/en/linkresolver/leprosy-an-update-definition-pathogenesis/S1578-2190(13)00143-1/?pubmed=true  a554-630 v104  aEICHELMANN 2013 english, EIGHELMANN 2013 spanish3 a<p>Leprosy is a chronic granulomatous disease caused by the bacillus Mycobacterium leprae. It primarily affects the skin and peripheral nerves and is still endemic in various regions of the world. Clinical presentation depends on the patient's immune status at the time of infection and during the course of the disease. Leprosy is associated with disability and marginalization. Diagnosis is clinical and is made when the patient has at least 1 of the following cardinal signs specified by the World Health Organization: hypopigmented or erythematous macules with sensory loss; thickened peripheral nerves; or positive acid-fast skin smear or skin biopsy with loss of adnexa at affected sites. Leprosy is treated with a multidrug combination of rifampicin, clofazimine, and dapsone. Two main regimens are used depending on whether the patient has paucibacillary or multibacillary disease. </p>  a1578-2190